Fixed Dosing of Liposomal Amphotericin B in Morbidly Obese Individuals.

Authors :: Wasmann, Roeland E
Smit, Cornelis
Dongen, Eric P H van
Wiezer, René M J
Adler-Moore, Jill
Beer, Yvo M de
Burger, David M
Knibbe, Catherijne A J
Brüggemann, Roger J M
Source :: Clinical Infectious Diseases. 5/15/2020, Vol. 79 Issue 10, p2213-2215. 3p.
Publication Year :: 2020
Abstract: In this prospective study, we examined the pharmacokinetics of 1 and 2 mg/kg liposomal amphotericin B in 16 morbidly obese individuals (104–177 kg). Body size had no effect on clearance. We recommend a fixed dose in patients ≥100 kg (ie, 300 or 500 mg rather than the current dose of 3 and 5 mg/kg, respectively). Clinical Trials Registration NCT02320604. [ABSTRACT FROM AUTHOR]